CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter ended December 31, 2015 and full year 2015 and corporate highlights.
“Catabasis continues to advance our clinical-stage programs,” commented Jill C. Milne, Ph.D., Chief Executive Officer of Catabasis. “We recently announced positive top-line results from Part A of our MoveDMD trial of CAT-1004, which we believe has the potential to be a disease-modifying therapy in patients with Duchenne muscular dystrophy (DMD), regardless of the underlying mutation. Based on these positive results, we are preparing to launch Part B of the MoveDMD trial during the first half of the year, subject to regulatory approval of our proposed protocol. The Phase 2a trial of CAT-2054 in hypercholesterolemia is substantially enrolled. Additionally, we have generated promising pre-clinical results with the CAT-2000 series in non-alcoholic steatohepatitis (NASH). We expect 2016 will be a pivotal year for Catabasis. We anticipate Phase 2 data for CAT-1004 in DMD late this year and Phase 2a data for CAT-2054 in hypercholesterolemia in Q3.”
